Trial Profile

Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary)
Indications Autoimmune diseases of the nervous system; Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Therapeutic Use
Acronyms OPA

Most Recent Events

06 Feb 2024 Planned End Date changed from 1 Sep 2021 to 30 Oct 2025.
06 Feb 2024 Planned primary completion date changed from 1 Mar 2021 to 30 Jun 2025.
11 Dec 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com